增加局部糖皮质激素用药频率对术后顽固性黄斑水肿患者有益
随机临床试验比较标准与高频局部糖皮质激素治疗术后黄斑水肿,第12周时两组最佳矫正视力与黄斑中心凹厚度变化无显著差异;第2组8例持续水肿者交叉至泼尼松龙醋酸盐每小时一次后,第24周视力与厚度较第12周显著改善。
要点
- 术后黄斑水肿患者初始用酮咯酸每日四次+泼尼松龙醋酸盐每日四次,12周时视力与厚度改善与高频组无显著差异。
- 第2组8例12周持续水肿者交叉至泼尼松龙醋酸盐每小时一次,第24周视力较第12周改善+7.0字母(P=.01)。
- 交叉后第24周黄斑中心凹厚度较第12周变化-108.25 μm(P=.04)。
核心结论
- 作者认为术后黄斑水肿患者初始应接受酮咯酸每日四次和泼尼松龙醋酸盐每日四次治疗,若12周后水肿未消退,换用酮咯酸每日四次和泼尼松龙醋酸盐每小时一次可能有益。
研究设计与样本
- 随机临床试验,将术后黄斑水肿受试者分层为白内障术后黄斑水肿(PCSME)和其他手术后黄斑水肿(POSME),随机分为第1组(酮咯酸每日四次+1%泼尼松龙醋酸盐每小时一次清醒时使用)和第2组(酮咯酸每日四次+1%泼尼松龙醋酸盐每日四次)。
- 第1组22例(PCSME 13例,POSME 9例),第2组20例(PCSME 12例,POSME 8例)。
主要发现
- 第12周时,第1组与第2组最佳矫正视力(ETDRS字母)较基线变化分别为+11.6与+8.5(P=.32)。
- 第12周时,PCSME亚组第1组与第2组视力较基线变化分别为+10.6与+7.8(P=.23);POSME亚组分别为+13.1与+9.4(P=.47)。
- 第12周时,第1组与第2组黄斑中心凹厚度(CST,μm)较基线变化分别为-100.8与-63.9(P=.30)。
- 第12周时,第1组与第2组眼压较基线变化分别为+2.6与+1.7 mm Hg(P=.52)。
- 第2组8例第12周有残留黄斑水肿者换用泼尼松龙醋酸盐每小时一次,第24周时视力较第12周变化+7.0字母(P=.01),CST较第12周变化-108.25 μm(P=.04)。
临床怎么用
- 作者认为术后黄斑水肿患者初始应接受酮咯酸每日四次和泼尼松龙醋酸盐每日四次治疗。
- 作者认为若12周后水肿未消退,换用酮咯酸每日四次和泼尼松龙醋酸盐每小时一次可能有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare standard and frequent topical steroids for postsurgical macular edema (ME). DESIGN: Randomized clinical trial. METHODS: Subjects with postsurgical ME stratified into post-cataract surgery ME (PCSME) and post-other surgery ME (POSME) were randomized to ketorolac 4 times a day (qid) + 1% prednisolone acetate (PA) every hour while awake (q1hWA, Group 1) or qid (Group 2). Mean change from baseline best-corrected visual acuity (BCVA) was determined at week 12, after which group 2 subjects with persistent edema were crossed over to PA q1hWA. RESULTS: Twenty-two subjects (13 PCSME and 9 POSME) were randomized to Group 1 and 20 (12 PCSME and 8 POSME) to Group 2. At week 12, change from baseline BCVA (ETDRS letters) in Group 1 vs 2 was +11.6 vs +8.5 (P = .32) and for subgroups was +10.6 vs +7.8 (P = .23) for PCSME and +13.1 vs +9.4 (P = .47) for POSME. Mean change from baseline central subfield thickness (CST, μm) at week 12 in Group 1 vs 2 was -100.8 vs -63.9 (P = .30). Mean change from baseline intraocular pressure was +2.6 vs +1.7 mm Hg (P = .52). Eight subjects in Group 2 with residual ME at week 12 were switched to PA q1hWA and at week 24, the mean changes from week 12 BCVA and CST were +7.0 letters (P = .01) and -108.25 μm (P = .04). CONCLUSIONS: Our data suggest that patients with postsurgical ME should initially be treated with ketorolac and PA qid, but if edema does not resolve after 12 weeks, a switch to ketorolac qid and PA q1hWA may provide benefit.
引用
- Campochiaro PA, Han YS, Mir TA, et al. Increased Frequency of Topical Steroids Provides Benefit in Patients With Recalcitrant Postsurgical Macular Edema. Am J Ophthalmol. 2017. PMID: 28392176. doi:10.1016/j.ajo.2017.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。